AME Study of [14C]-PC14586 in Healthy Male Participants

Healthy Male Volunteers Clinical Trial

Official title:

A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-PC14586 Following a Single Oral Dose in Healthy Male Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05523687
• Other study ID #: PMV-586-103
• Status: Completed
• Phase: Phase 1
• Start date: September 6, 2022
• Est. completion date: November 30, 2022

Study information

• Verified date: December 2022
• Source: PMV Pharmaceuticals, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the PK and rates of elimination and mass balance of total radioactivity from [14C]-PC14586

Description:

PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation. The study will assess the PK, absorption, metabolism, and excretion of [14C]-PC14586 following a single dose in healthy male participants.

The aim is to recruit approximately 8 participants with a minimum number of 6 evaluable participants.

Each participant will be admitted to the study site pre-dose on Day -1 and will remain at the study site until at least Day 14. Participants will receive a single administration of [14C]-PC14586 as oral capsules on Day 1. During this study, whole blood, plasma, urine, feces, and vomit samples (if presented) will be collected at various timepoints to characterize the absorption, metabolism, excretion, and PK of [14C]-PC14586.

The duration of the residential period will be evaluated following the administration of [14C]-PC14586 and may be extended to ensure recovery of at least 90% of the total radioactivity, or until less than 1% of dose is recovered in urine and/or feces.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: November 30, 2022
• Est. primary completion date: November 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Healthy, non-smoking males of any race, between 18 and 55 years of age, with BMI between 18.0 and 32.0 kg/m2 inclusive.

2. In good health, determined by no clinically significant findings from medical history and evaluations at screening and check-in as assessed by the investigator.

3. Agree to use a highly effective method of contraception from check-in through 90 days after discharge.

4. History of a minimum of 1 bowel movement per day.

5. Creatinine clearance =90 mL/min determined using the Cockcroft-Gault equation.

6. Able to swallow capsules.

Exclusion Criteria:

1. Significant history or clinical manifestation of any medical condition, disease or disorder, as determined by the investigator.

2. Blood pressure >140 mm systolic or >90 diastolic at screening or Day -1.

3. Positive hepatitis panel and/or positive human immunodeficiency virus test

4. Use or intend to use any prescription and/or nonprescription medications/products within14 days prior to check-in.

5. Participation in a clinical study involving last administration of an investigational drug within the past 30 days prior to dosing, or within 5 half-lives of the IMP, whichever is longer, or who have participated in more than 3 radiolabeled drug studies in the last 12 months.

6. Participants who have previously completed or withdrawn from this study or any other study investigating PC14586, or have previously received PC14586.

7. Participants with a history of alcoholism or drug/chemical abuse within 2 years prior to check-in, use of tobacco or nicotine-containing products within 3 months prior to check-in or with a positive drug and/or alcohol test result at check-in.

8. A positive p53 Y220C germline test at screening

Related Conditions & MeSH terms

• Healthy Male Volunteers

Intervention

Drug:
• [14C]-PC14586
Single, oral dose of [14C]-PC14586

Locations

Country	Name	City	State
United States	Labcorp Clinical Research Unit Inc.	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
PMV Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characterize Maximum Plasma Concentration (Cmax) of PC14586 and PC14586 metabolite M1 (PC16163).	Determine Cmax for PC14586 and PC16163 in plasma.	1 month
Primary	Characterize Time to Maximum Plasma Concentration (tmax) of PC14586 and PC14586 metabolite M1 (PC16163).	Determine tmax for PC14586 and PC16163 in plasma.	1 month
Primary	Characterize Total Drug Exposure (AUC0-inf) of PC14586 and PC14586 metabolite M1 (PC16163).	Determine AUC0-inf for PC14586 and PC16163 in plasma.	1 month
Primary	Characterize Total Drug Exposure to the last measurable concentration (AUC0-t) of PC14586 and PC14586 metabolite M1 (PC16163).	Determine AUC0-t for PC14586 and PC16163 in plasma.	1 month
Primary	Characterize the Half-Life (t 1/2) of PC14586 and PC14586 metabolite M1 (PC16163).	Determine t 1/2 for PC14586 and PC16163 in plasma.	1 month
Primary	Characterize the Clearance (CL/F) of PC14586 and PC14586 metabolite M1 (PC16163) after oral administration.	Determine CL/F for PC14586 and PC16163 in plasma.	1 month
Primary	Characterize the Volume of Distribution (Vd/F) of PC14586 and PC14586 metabolite M1 (PC16163) after oral administration.	Determine Vd/F for PC14586 and PC16163 in plasma.	1 month
Primary	Determine the total radioactivity in whole blood and plasma of PC14586 and PC14586 metabolite M1 (PC16163).	Determine total radioactivity for PC14586 and PC16163 in whole blood and plasma.	1 month
Primary	Characterize total radioactivity (Xlast, feces) of PC14586 excreted in feces.	Determine total radioactivity of PC14586 excreted in feces	1 month
Primary	Characterize the half life of total radioactivity (Xt1-t2, feces) of PC14586 excreted in feces.	Determine half life of total radioactivity of PC14586 excreted in feces.	1 month
Primary	Characterize the fraction excreted of total radioactivity (fe last, feces) of PC14586 in feces.	Determine the fraction excreted of total radioactivity of PC14586 in feces.	1 month
Primary	Characterize the half-life of fraction excreted of total radioactivity (fe t1-t2, feces) of PC14586 in feces.	Determine half-life of fraction excreted of total radioactivity of PC14586 in feces.	1 month
Primary	Characterize total radioactivity (Xlast, urine) of PC14586 excreted in urine.	Determine total radioactivity of PC14586 excreted in urine.	1 month
Primary	Characterize the half life of total radioactivity (Xt1-t2, urine) of PC14586 excreted in urine.	Determine half life of total radioactivity of PC14586 excreted in urine.	1 month
Primary	Characterize the fraction excreted of total radioactivity (fe last, urine) of PC14586 in urine.	Determine the fraction excreted of total radioactivity of PC14586 in urine.	1 month
Primary	Characterize the half-life of fraction excreted of total radioactivity (fe t1-t2, urine) of PC14586 in urine.	Determine half-life of fraction excreted of total radioactivity of PC14586 in urine.	1 month
Primary	Characterize the renal clearance (CLr) of PC14586 in urine.	Determine the renal clearance of PC14586 in urine.	1 month
Secondary	Identification of PC14586 metabolite profiles in plasma, urine and feces.	Identification of PC14586 metabolites in plasma (>10% relative total drug related exposure) and excreta (>10% of excreted dose).	1 month
Secondary	Identification of the incidence and severity of adverse events after administration of PC14586.	Number of participants with adverse events.	1 month
Secondary	Identification of the incidence of laboratory abnormalities based on hematology, clinical chemistry and urine test results of PC14586.	Number of participants with an incidence of laboratory abnormalities in test results.	1 month
Secondary	Identification of 12-lead electrocardiogram (ECG) abnormalities after a single dose of PC14586.	Number of participants with abnormal 12-lead ECG results.	1 month
Secondary	Identification of abnormal blood pressure after a single dose of PC14586.	Number of participants with abnormal blood pressure.	1 month
Secondary	Identification of abnormal pulse rate after a single dose of PC14586.	Number of participants with abnormal pulse rate.	1 month
Secondary	Identification of abnormal oral body temperature after a single dose of PC14586.	Number of participants with abnormal oral body temperature.	1 month